Developing Resistant Models to Diverse ADC Drugs

Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer therapies.  However, primary and secondary resistance is frequently observed.  The successful development of next generation ADCs necessitates the establishment of tumor models that address the mechanism of action underlying this resistance.

At the 2025 World ADC London conference, WuXi Biology presented a poster showcasing the development of various ADC-resistant cell lines through processes such as drug-induced resistance or efflux pump overexpression.  The authors describe how the resistant properties of these models have been validated both in vitro and in vivo. These drug resistant models offer crucial tools that can assist in the discovery and optimization of next-generation ADCs.

Poster_World ADC London Conference 2025_Developing Resistant Models to Diverse ADC Drugs

Download